The present disclosure pertains generally, but not by way of limitation, to orthopedic implants and methods of treatment. More particularly, the present invention relates to a tendon repair implant, such as one that is engineered for arthroscopic placement over or in the area of a full thickness tear of the supraspinatus tendon of the shoulder
With its complexity, range of motion and extensive use, a common soft tissue injury is damage to the rotator cuff or rotator cuff tendons. Damage to the rotator cuff is a potentially serious medical condition that may occur during hyperextension, from an acute traumatic tear or from overuse of the joint. The accepted treatment for a full thickness rotator cuff tear includes reattaching the torn tendon to the humeral head using sutures. In treating large or massive full thickness tears, accepted practice also can include the placement of scaffolds and patches over the repaired tendon to mechanically augment the strength of the repaired tendon.
For partial thickness rotator cuff tears, and for full thickness tears that do not require mechanical augmentation, a bioinductive implant has been used to induce new tendinous tissue, which biologically augments the tendon and enables healing of partial thickness defects, as well as improved reattachment of full thickness repairs to the humeral head. The healing response associated the bioinductive implant results in integration of the newly induced tissue with the native tissues, which provides a biological connection for load sharing that is not dependent on sutures or some other mechanical anchor or connector. This biological connection is a critically important aspect of biological augmentation because long-term load sharing is not dependent on sutures, which may migrate through the tissues, but is ensured by the continuity of the collagen fibers in the induced tissue with native tissues. The bioinductive implant, however, does not provide any immediate mechanical augmentation; rather, the newly induced tissue provides biological augmentation over time.
Current scaffolds or patches used to augment rotator cuff repairs are designed to provide initial mechanical augmentation, i.e., added strength, at the time of surgery. Use of these implants, however, often do not provide any benefit beyond the immediate postoperative period. Thus, there is a need for an implant that not only provides initial mechanical augmentation, but also provides improved healing.
In accordance with aspects of the disclosure, a tendon repair implant is provided that combines the benefits of a bioinductive implant, which biologically augments a repaired tendon and improves healing, with an implant that provide mechanical augmentation for added strength in the early postoperative period. An example tendon repair implant comprises a sheet-like structure including a first component configured to have an initial tensile modulus of about 5 megapascals (MPa) to 50 MPa and comprising a plurality of pores for tissue in-growth and a second component configured to have an initial tensile modulus of about 50 MPa to 150 MPa; wherein the sheet-like structure conforms to the surface of the tendon and is configured to have an initial load share representing about 50% or more of the load of the tendon when affixed to the tendon.
Alternatively or additionally to the above example, in another example, the first component and the second component form discrete layers.
Alternatively or additionally to the examples above, in another example, the second component is intermixed with the first component to form a composite material.
Alternatively or additionally to the examples above, in another example, about 50% or more of the load of the tendon comprises between 25 Newtons (N) and 50 N.
Alternatively or additionally to the examples above, in another example, the sheet-like structure is configured to degrade in tensile strength from an initial tensile strength thereby sharing less of the load of the tendon over time but retain at least about 50% of the initial load share of the sheet-like implant three months after being affixed to the tendon.
Alternatively or additionally to the examples above, in another example, wherein to retain at least about 50% of the initial load share of the sheet-like implant at three months, the sheet-like structure is configured to retain at least about 70% of the initial tensile strength three months after being affixed to the tendon and to retain at least about 50% of the initial tensile strength and about 50% of an initial compressive modulus three months after being affixed to the tendon.
Alternatively or additionally to the examples above, in another example, the first component is configured to degrade in tensile strength from an initial tensile strength at a first rate and the second component is configured to degrade in tensile strength from an initial tensile strength at a second rate different from the first rate.
Alternatively or additionally to the examples above, in another example, the second rate is slower than the first rate.
Alternatively or additionally to the examples above, in another example, the first component comprises a bioresorbable material.
Alternatively or additionally to the examples above, in another example, the second component comprises a bioresorbable material.
Alternatively or additionally to the examples above, in another example, the first component comprises a polymer material.
Alternatively or additionally to the examples above, in another example, the second component comprises a polymer material.
Alternatively or additionally to the examples above, in another example, the sheet-like structure is further configured to be attached to the surface of the tendon without significant pre-loading or significant pre-stretching.
Alternatively or additionally to the examples above, in another example, the sheet-like structure has one or more agents affixed thereto which promote tissue in-growth.
Alternatively or additionally to the examples above, in another example, the pores have sizes between about 20 microns and 400 microns.
Alternatively or additionally to the examples above, in another example, the sheet-like structure is defined by a longitudinal dimension, a lateral dimension, and a thickness dimension, wherein the longitudinal dimension is greater than the lateral dimension and the thickness dimension, and wherein the sheet-like structure further comprises one or more longitudinal pathways extending along the longitudinal dimension of the sheet-like structure.
Alternatively or additionally to the examples above, in another example, the sheet-like structure has a maximum of about 0.5% creep over three months. Alternatively or additionally to the examples above, in another example, further comprising a third component configured to have an initial tensile modulus of about 5 MPa to 50 MPa.
Another example tendon repair implant comprises a sheet-like structure including a first component configured to have an initial tensile modulus of about 5 megapascals (MPa) to 20 MPa and comprising a plurality of pores for tissue in-growth and a second component configured to have an initial tensile modulus of about 20 MPa to 50 MPa; wherein the sheet-like structure conforms to the surface of the tendon and is configured to have an initial load share representing about 10% to 50% of the load of the tendon when affixed to the tendon.
Alternatively or additionally to the examples above, in another example, the first component and the second component form discrete layers.
Alternatively or additionally to the examples above, in another example, the second component is intermixed with the first component to form a composite material.
Alternatively or additionally to the examples above, in another example, about 10% to 50% the load of the tendon comprises between 5 Newtons (N) and 25 N.
Alternatively or additionally to the examples above, in another example, the sheet-like structure is configured to degrade in tensile strength from an initial tensile strength thereby sharing less of the load of the tendon over time but retain at least about 50% of the initial load share of the sheet-like implant three months after being affixed to the tendon.
Alternatively or additionally to the examples above, in another example, to retain at least about 50% of the initial load share of the sheet-like implant at three months, the sheet-like structure is configured to retain at least about 70% of the initial tensile strength three months after being affixed to the tendon and to retain at least about 50% of the initial tensile strength and about 50% of an initial compressive modulus three months after being affixed to the tendon.
Alternatively or additionally to the examples above, in another example, the first component is configured to degrade in tensile strength from an initial tensile strength at a first rate and the second component is configured to degrade in tensile strength from an initial tensile strength at a second rate different from the first rate.
Alternatively or additionally to the examples above, in another example, the second rate is slower than the first rate.
Alternatively or additionally to the examples above, in another example, the first component comprises a bioresorbable material.
Alternatively or additionally to the examples above, in another example, the second component comprises a bioresorbable material.
Alternatively or additionally to the examples above, in another example, the first component comprises a polymer material.
Alternatively or additionally to the examples above, in another example, the second component comprises a polymer material.
Alternatively or additionally to the examples above, in another example, the sheet-like structure is further configured to be attached to the surface of the tendon without significant pre-loading or significant pre-stretching.
Alternatively or additionally to the examples above, in another example, the sheet-like structure has one or more agents affixed thereto which promote tissue in-growth.
Alternatively or additionally to the examples above, in another example, the pores have sizes between about 20 microns and 400 microns.
Alternatively or additionally to the examples above, in another example, the sheet-like structure is defined by a longitudinal dimension, a lateral dimension, and a thickness dimension, wherein the longitudinal dimension is greater than the lateral dimension and the thickness dimension, and wherein the sheet-like structure further comprises one or more longitudinal pathways extending along the longitudinal dimension of the sheet-like structure.
Alternatively or additionally to the examples above, in another example, the sheet-like structure has a maximum of about 0.5% creep over three months.
Alternatively or additionally to the examples above, in another example, further comprising a third component configured to have an initial tensile modulus of about 20 MPa to 50 MPa.
Another example tendon repair implant for repair of a complete or partial thickness tear of a supraspinatus tendon having a load bearing direction, the tendon repair implant comprises a sheet-like structure having a longitudinal dimension, a lateral dimension, and a thickness dimension and configured to be affixed to a surface of the supraspinatus tendon such that the longitudinal dimension of the sheet-like structure extends generally parallel to the load bearing direction of the supraspinatus tendon, the sheet-like structure including a first component configured to have an initial tensile modulus of about 5 megapascals (MPa) to 50 MPa and comprising a plurality of pores for tissue in-growth and a plurality of longitudinal pathways that encourage tissue in-growth therein, wherein the longitudinal pathways extend along the longitudinal dimension of the sheet-like structure and have cross sections of about 150 microns to 200 microns and a second component configured to have an initial tensile modulus of about 50 MPa to 150 MPa; wherein when affixed to the surface of the supraspinatus tendon, the sheet-like structure is configured to initially share about 50% or more of a load applied to the supraspinatus tendon.
Alternatively or additionally to the examples above, in another example, the first component and the second component form discrete layers.
Alternatively or additionally to the examples above, in another example, the second component is intermixed with the first component to form a composite material.
Alternatively or additionally to the examples above, in another example, the pores range in size from about 20 to 400 microns.
Another example tendon repair implant for repair of a complete or partial thickness tear of a supraspinatus tendon having a load bearing direction, the tendon repair implant comprises a sheet-like structure having a longitudinal dimension, a lateral dimension, and a thickness dimension and configured to be affixed to a surface of the supraspinatus tendon such that the longitudinal dimension of the sheet-like structure extends generally parallel to the load bearing direction of the supraspinatus tendon, the sheet-like structure including a first component configured to have an initial tensile modulus of about 5 megapascals (MPa) to 20 MPa and comprising a plurality of pores for tissue in-growth and a plurality of longitudinal pathways that encourage tissue in-growth therein, wherein the longitudinal pathways extend along the longitudinal dimension of the sheet-like structure and have cross sections of about 150 microns to 200 microns and a second component configured to have an initial tensile modulus of about 20 MPa to 50 MPa; wherein when affixed to the surface of the supraspinatus tendon, the sheet-like structure is configured to have an initial load share representing about 10% to 50% of a load applied to the supraspinatus tendon.
Alternatively or additionally to the examples above, in another example, the first component and the second component form discrete layers.
Alternatively or additionally to the examples above, in another example, the second component is intermixed with the first component to form a composite material.
Alternatively or additionally to the examples above, in another example, the pores range in size from about 20 to 400 microns.
An example method for manufacturing a tendon repair implant for repair of a complete or partial thickness tear of a tendon comprises rotating a mandrel at a first speed; collecting a plurality of fibers on the rotating mandrel at the first speed; after collecting a plurality of fibers on the rotating mandrel at the first speed, rotating the mandrel at a second speed, different than the first speed; and collecting a plurality of fibers on the rotating mandrel at the second speed.
The above summary of some examples and embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Brief Description of the Drawings, and Detailed Description, which follow, more particularly exemplify these embodiments, but are also intended as exemplary and not limiting.
While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the claimed invention. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate example embodiments of the claimed invention.
Definitions of certain terms are provided below and shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same or substantially the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (i.e., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include or otherwise refer to singular as well as plural referents, unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed to include “and/or,” unless the content clearly dictates otherwise.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to affect such feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or able to be arranged with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.
As disclosed by Ball et al. in U.S. Patent Publication No. US 2008/0188936 A1 and as illustrated in
The insertion of these tendons as a continuous cuff 10 around the humeral head 17 permits the cuff muscles to provide an infinite variety of moments to rotate the humerus 14 and to oppose unwanted components of the deltoid and pectoralis muscle forces. The insertion of the infraspinatus 13 overlaps that of the supraspinatus 18 to some extent. Each of the other tendons 16, 15 also interlaces its fibers to some extent with its neighbor's tendons. The tendons splay out and interdigitate to form a common continuous insertion on the humerus 14.
The rotator cuff muscles 10 are critical elements of this shoulder muscle balance equation. The human shoulder has no fixed axis. In a specified position, activation of a muscle creates a unique set of rotational moments. For example, the anterior deltoid can exert moments in forward elevation, internal rotation, and cross-body movement. If forward elevation is to occur without rotation, the cross-body and internal rotation moments of this muscle must be neutralized by other muscles, such as the posterior deltoid and infraspinatus. The timing and magnitude of these balancing muscle effects must be precisely coordinated to avoid unwanted directions of humeral motion. Thus the simplified view of muscles as isolated motors, or as members of force couples must give way to an understanding that all shoulder muscles function together in a precisely coordinated way—opposing muscles canceling out undesired elements leaving only the net torque necessary to produce the desired action. Injury to any of these soft tissues can greatly inhibit ranges and types of motion of the arm.
The mechanics of the rotator cuff 10 are complex. The cuff muscles 10 rotate the humerus 14 with respect to the scapula 12, compress the humeral head 17 into the glenoid fossa providing a critical stabilizing mechanism to the shoulder (known as concavity compression), and provide muscular balance. The supraspinatus and infraspinatus provide 45 percent of abduction and 90 percent of external rotation strength. The supraspinatus and deltoid muscles are equally responsible for producing torque about the shoulder joint in the functional planes of motion.
With its complexity, range of motion and extensive use, a fairly common soft tissue injury is damage to the rotator cuff or rotator cuff tendons. Damage to the rotator cuff is a potentially serious medical condition that may occur during hyperextension, from an acute traumatic tear or from overuse of the joint. With its critical role in abduction, rotational strength and torque production, the most common injury associated with the rotator cuff region is a strain or tear involving the supraspinatus tendon. A tear in the supraspinatus tendon 19 is schematically depicted in
The accepted treatment for a full thickness tear or a partial thickness tear greater than 50% includes reattaching the torn tendon to the humeral head using sutures. For the partial thickness tears greater than 50%, the tear is often completed to a full thickness tear by cutting the tendon prior to reattachment of the tendon. In treating a full thickness tear or partial thickness tear of greater than 50% after completing the tear by cutting the tendon, accepted practice also can include the placement of scaffolds and patches over the repaired tendon to shield the sutured or repaired tendon area from anatomical load during rehabilitation. For example, Wright Medical discloses that the GraftJacket® can be used to augment a suture repaired tendon in large and massive full thickness tears or smaller full-thickness tears in a shoulder having severely degenerated tissue. However, it is recognized that excessive shielding of the tendon from load can lead to atrophy and degeneration of the native tendon.
It is known that, for the rotator cuff, allowing the tendon to experience full anatomical load during recovery after repairing the tendon tear with sutures will result in a 20-60% failure rate. Ball et al. (US Patent Appl. Pub. No. 2008/0188936 A1) disclose an implant that provides a healing modality that shields the tendon from most of the anatomical loads in the early part of the recovery period, and gradually experience increasing loads as the repair heals to full strength. Ball et al. disclose the strength of the surgical repair, expressed as percent strength of the final healed repair, begins post-surgically at the strength of the suture-to-tissue connection alone. In their illustrated example, the suture-to-tissue connection represents about 25% of the strength. The augmentation implant initially receives the 75% of the loads experienced during recovery through high initial strength. Gradually, the ratio of load sharing shifts to the suture-to-tissue connection as the repair heals and gains strength, while the implant is simultaneously absorbed by the body. Strength retention is defined to refer to the amount of strength that a material maintains over a period of time following implantation into a human or animal. For example, if the tensile strength of an absorbable mesh or fiber decreases by half over three months when implanted into an animal or human, the mesh or fiber's strength retention at 3 months would be 50%.
However, some implants may not provide biological continuity between the implant and the tendon. For example, the suture connection may be the only means to off-load the tendon. It is contemplated that the implant may not carry any load if mechanical “conditioning” does not remove slack in the implant. Further, soon after surgery, if the sutures slip through the tissue, even slightly, the ability to off-load the tendon may be lost. Creep/stress relaxation may also limit the ability of the implant to carry the load long-term. Strain in the tendon is about 2% under normal loads, so an implant creep of only about 2% may completely eliminate the ability of the implant to provide augmentation). In some instances, the implant may not support or encourage tissue ingrowth. As a result, the implant may be incapable of remodeling and therefore cannot adapt to changing demands as rehabilitation progresses. These drawbacks of current implants are overcome by the current invention, which induces new tendinous tissue that integrates with the native tissues, providing continuity between the structures that is not dependent on mechanical connections for load sharing.
Scapula 23 includes an acromion 21. In
In some embodiments, the tendon repair implant is engineered to provide a combination of structural features, properties and functions that are particularly appropriate for treating a full thickness tear or a partial thickness tear of greater than 50%, without physically cutting, then suturing the tendon, as is typically done in treating full thickness tears or partial thickness tears greater than 50%. While the tendon repair implant 25 is described with respect to full thickness tears or a partial thickness tear of greater than 50%, it is contemplated that the implant 25 may also be used in a partial thickness tear of less than 50%. These features may include: rapid deployment and fixation by arthroscopic means that compliment current procedures; tensile properties that result in desired sharing of anatomical load between the implant and native tendon during rehabilitation; selected porosity and longitudinal pathways for tissue in-growth; sufficient cyclic straining of the implant, having new tissue in-growth, in the longitudinal direction to promote remodeling of new tissue to tendon-like tissue; induction of a healing response; and, the tendon repair implant is bioabsorbable or otherwise absorbable to provide transfer of additional load to native tendon over time.
In some embodiments, tendon repair implants are structured for rapid deployment and fixation by arthroscopic means to complement current techniques used to relieve impingement or restricted movement of tendon relative to bone, such as acromioplasty and tunneling procedures in partial thickness tear treatments. The tendon repair implant 25 is a generally sheet-like structure that has a surface that conforms to the tendon surface when implanted. Further, the physical properties of the implant may be such that no significant prestretching or pre-loading of the implant during placement is required for it to function in sharing a sufficient portion of the anatomical load with the native tendon, as discussed below. Stated another way, the tensile properties of the implant may be designed to share a sufficient portion of the anatomical load present during rehabilitation by laying the implant in surface to surface contact with the tendon without any significant wrinkles. Therefore, the tendon repair implant may be delivered in a folded, rolled or other reduced configuration through an arthroscopic instrument and spread out into the sheet-like shape with its surface in contact and generally conforming to the tendon surface without significant stretching before fixation to the tendon. Fixation may be accomplished via arthroscopic suturing or stapling techniques.
Current procedures for repairing full thickness tears or partial thickness tears greater than 50% include cutting and suturing of the tendon itself and may include the addition of an implant that is designed to shield the tendon repair area from experiencing stresses during use. With current stress shielding implants, the concern is the strain and load at which the implant versus the suture repair fails, as the goal is to prevent suture failure during excessive loading. In contrast, the tendon repair implants in some embodiments of the present disclosure have tensile properties to selectively share the anatomical load between damaged native tendon and the implant during the normal range of strains experienced during rehabilitation.
The tensile properties of some tendon repair implants described in the present disclosure are engineered to selectively share the anatomical load during rehabilitation. As installed over the damaged tendon, the tendon repair implant 25 and native tendon 22 are two generally parallel structures that each carry a portion of a load generated by contraction of the supraspinatus muscle 30. The relative load carried by each depends on the tensile properties of the each structure. As parallel structures, the tendon repair implant 25 and the native tendon 22 each experience similar strain under a given load, depending on the effectiveness of the attachment between the tendon and the implant. It is known that native tendon will fail at strains of about 8%, and in normal use tendons experience less than 5% strain. During rehabilitation after surgery, the native tendon is exposed to strains of about 0% to 3%. In some embodiments, tendon repair implants of the present disclosure are engineered with tensile properties in the range of 1% to 3% strain in order to properly share anatomical load during rehabilitation, as this is the range over which tensile properties affect the function of the implant. The tensile modulus of the implant relative to the tensile modulus of the tendon determines the load carried by the implant, i.e., the amount of load sharing. In some embodiments, the tensile modulus of the implant ranges from about 5 megapascals (MPa) to about 150 MPa in the range of 1% to 3% strain. In some embodiments, the tensile modulus of the implant may be about 20 to about 100 MPa in the range of 1% to 3% strain. The modulus value for a given material may be calculated from a best fit linear regression for data collected over the range of 1% to 3% strain. Depending upon the properties of the native tendon to which the implant is attached, this may result in initial load sharing following surgery with about 50% or more being carried by the implant. In some embodiments, about 10% to about 50% of the load may be carried by the implant. The load on the supraspinatus tendon during rehabilitation may be about 50 Newtons (N) to about 100 N, translating to a load on the implant of about 10 N to about 50 N. The tensile modulus can be measured with a 1 N preload at zero strain and elongation rate of 1% per second after positioning the sheet-like structure in a generally flat and non-wrinkled format.
In some embodiments, a tendon repair implant of the present disclosure includes a selected porosity and longitudinal pathways for tissue in-growth. In some useful embodiments, the sheet-like structure of the implant comprises a material defining a plurality of pores that encourage tissue growth therein. The porosity and tissue in-growth allows for new collagen to integrate with collagen of the native tendon for functional load carrying. A coating that encourages tissue growth or in-growth may be applied to the surfaces of the sheet-like structure. It will be appreciated that sheet-like structure may comprise various pore defining structures without deviating from the spirit and scope of the present description. In some embodiments, the sheet-like structure has a pore size in the range of about 20 to about 400 microns. In some embodiments the pore size is in the range of about 100 microns to about 300 microns, and in some embodiments it is about 150 to about 200 microns. The porosity may be about 30% to about 90%, or it may be within the range of at least about 50% to about 80%. Examples of pore defining structures are discussed in more detail below for specific embodiments, but may include, but not be limited to open cell foam structures, mesh structures, micromachined layered structures and structures comprising a plurality of fibers. In some embodiments, the fibers may be interlinked with one another. Various processes may be used to interlink the fibers with one another. Examples of processes that may be suitable in some applications include weaving, knitting, and braiding.
Tendon repair implants of the present invention may have a porosity greater than 50%, however, the porosity may be further structured to include tissue in-growth pathways in the longitudinal direction of the implant. Pathways may be included to extend through the thickness of the implant or laterally in the plane of the implant. Pathways may include segments extending longitudinally in the plane of the implant. In some embodiments, longitudinally extending pathways comprise a majority of the porosity with such pathway segments having cross sections of about 150 to about 200 microns. Longitudinal pathways may be open channels or lumens that extend in the longitudinal direction in the plane of the sheet-like structure when laying flat. They may be defined in the thickness of the sheet in the longitudinal direction. Further, these longitudinal pathways may generally be maintained when the implant is subjected to longitudinal loads experienced during rehabilitation.
A tendon repair implant may include tensile properties that allow for cyclic straining of the implant and new tissue in-growth to cause and facilitate remodeling of this new tissue to a more organized structure resembling tendon-like tissue. In some embodiments, the new tissue, based on the tensile properties of the implant, experiences tendon-like strain during rehabilitation. The tendon-like tissue, which may not be as strong as native tendon, has added load bearing strength in the longitudinal direction relative to unorganized tissue. This remodeling of tissue begins within 4 to 8 weeks after implant and continues for months. The strength of the new tissue continues to increase as collagen fibers become more oriented due to the proper strain signal resulting from the properties of the implant. To facilitate cyclic loading, the tendon repair implant may have a compressive modulus greater than the native tendon. A published value for the compressive modulus of the supraspinatus tendon is in the range of 0.02-0.09 MPa (J Biomech Eng 2001, 123:47-51). In some embodiments, the implant provided by the implantable device should have a higher compressive modulus than the tendon to prevent collapse of pores in the implant. The compressive modulus may be at least about 0.1 MPa, or at least about 0.2 MPa.
In some embodiments, the tendon repair implant is bioresorbable, biodegradable or otherwise absorbable to provide transfer of additional load to native tendon over time. By 2-3 months after implantation, the new tissue in-growth should have gained strength through remodeling and it may be desirable to transfer more load from the implant to the new tissue and native tendon combination. Absorption of the implant enables the new tissue, in combination with the native tendon, to carry all of the load and develop optimal collagen fiber alignment. Further, absorption avoids potential long-term problems with particles from non-absorbable materials. The tissue within the device implant will typically be developing and organizing during the first one to three months after implantation, so load sharing with the implant is desired in some embodiments. After three months the tissue will typically be remodeling, so the mechanical properties of portions of the implant may gradually decline to zero to enable the new tissue to be subjected to load without the implant bearing any of the load. If the implant loses modulus faster than it loses strength, then the relative loads on the implant will be less at three months than when first implanted. For example, if the modulus of the implant drops 50% to 25 MPa at three months, then 2% strain of the implant would require a stress of only about 0.5 MPa. At the same time, if the strength of the implant drops about 30% to 3.5 MPa, then the strength of the implant will be about seven times the anticipated loads at three months, compared to about five times when first implanted. Therefore, with the design criteria provided above, tensile failure of the implant during the first three months should be unlikely. Accordingly, the following specifications for degradation rate are recommended in some embodiments: an ultimate tensile strength of at least 70% strength retention at three months; tensile and compressive modulus of at least 50% strength retention at three months; and no minimum specification for strength and modulus at 6 months. The device may be designed to have a degradation profile such that it is at least 85% degraded in less than 1 to 2 years after implantation.
Cyclic creep is another design constraint to be considered in some embodiments. A strain of about 2% with a 30 millimeter (mm) long implant will result in an elongation of about only 0.6 mm. Therefore, very little cyclic creep can be tolerated in these embodiments to ensure that the implant will undergo strain with each load cycle. A test where a proposed implant design is cyclically strained to 2% at 0.5 Hertz with rest periods for 8 hours provides 9000 cycles, which likely exceeds the number of cycles experienced in three months of rehabilitation of a patient's joint. Incorporation of relaxation times should be considered in such testing. In some embodiments, a maximum of about 0.5% creep is an acceptable specification.
In some useful embodiments, the tendon repair implant comprises one or more bioabsorbable materials. Examples of bioabsorbable materials that may be suitable in some applications include those in the following list, which is not exhaustive: polylactide, poly-L-lactide (PLLA), poly-D-lactide (PDLA), polyglycolide (PGA), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester; poly(amino acids), poly(alphahydroxy acid) or related copolymers materials.
The tendon repair implant may be configured to allow loading and retention of biologic growth factors. The implant and/or the growth factors may be configured to controllably release the growth factors. The implant may be configured to allow transmission of body fluid to remove any degradation by-products in conjunction with a potential elution profile of biologics. The implant may also include platelet rich plasma at the time of implant or other biologic factor to promote healing and tissue formation.
A tendon repair implant of the present invention can include multiple layers or surface coatings. As implanted, the bursal side of the implant can include a layer or surface that will preferably slide against tissue without adherence. The tendon side of the implant may include a layer or coating that is more compatible with fixation to the tendon surface.
Various materials and formats may be used to produce tendon repair implants of the present invention. Each material and format is engineered to include selected material properties in the ranges discussed above. Material properties can be altered in the materials making up the sheet like structure or by altering the format or pattern of the material to adjust physical properties of the composite structure.
While some previous implants may encourage rapid tissue ingrowth (e.g., blood vessels and fibroblasts), the previous implants may not provide any additional strength to the damaged tendon until new tissue is induced. In some instances, it may be desirable to provide a tendon repair implant 25 which provides immediate mechanical strength to the tendon and also induces a healing response. This may be accomplished with a layered or composited implant 25. The implant 25 may include a first layer or component 50 having a first set of properties and a second layer or component 52 having a second set of properties. In some instances, the first layer 50 may be a bioinductive implant or component and the second layer 52 may be a higher-strength component. In some instances, the bioinductive component 50 and the higher-strength component 52 may be formed as a laminated structure. For example, the bioinductive component 50 and the higher-strength component 52 may be formed as discrete layers, as shown in
The bioinductive component 50 may include a selected porosity and longitudinal pathways to encourage tissue in-growth. In some useful embodiments, the sheet-like structure of the bioinductive component 50 comprises a material defining a plurality of pores that encourage tissue growth therein. The porosity and tissue in-growth allows for new collagen to integrate with collagen of the native tendon for functional load carrying. A coating that encourages tissue growth or in-growth may be applied to the surfaces of the bioinductive component 50. It will be appreciated that sheet-like structure may comprise various pore defining structures without deviating from the spirit and scope of the present description. In some embodiments, the sheet-like structure has a pore size in the range of about 20 to about 400 microns. In some embodiments the pore size is in the range of about 100 microns to about 300 microns, and in some embodiments it is about 150 to about 200 microns. The porosity may be about 30% to about 90%, or it may be within the range of at least about 50% to about 80%. In some instances, the bioinductive component may have a dry density in the range of 0.2 grams per cubic centimeter (g/cm3) to 0.4 g/cm3. Examples of pore defining structures are discussed in more detail below for specific embodiments, but may include, but not be limited to open cell foam structures, mesh structures, micromachined layered structures and structures comprising a plurality of fibers. In some embodiments, the fibers may be interlinked with one another. Various processes may be used to interlink the fibers with one another. Examples of processes that may be suitable in some applications include weaving, knitting, and braiding.
The porosity of the bioinductive component 50 may be further structured to include tissue in-growth pathways in the longitudinal direction of the implant. Pathways may be included to extend through the thickness of the implant or laterally in the plane of the bioinductive component 50. Pathways may include segments extending longitudinally in the plane of the bioinductive component 50. In some embodiments, longitudinally extending pathways comprise a majority of the porosity with such pathway segments having cross sections of about 150 to about 200 microns. Longitudinal pathways may be open channels or lumens that extend in the longitudinal direction in the plane of the sheet-like structure when laying flat. They may be defined in the thickness of the sheet in the longitudinal direction. Further, these longitudinal pathways may generally be maintained when the implant 25 is subjected to longitudinal loads experienced during rehabilitation. However, large (3-5 centimeters) and massive (>5 centimeters) tears may involve more than one tendon. The collagen fibers in the different tendons will be oriented in different directions. Therefore, uniform orientation of the pathways and/or fibers of the implant 25 is not necessarily needed. It is contemplated that at least some of the pathways and/or fibers may be oriented in the lateral direction or at varying angles between the longitudinal and lateral directions.
It is contemplated that the initial tensile modulus of the bioinductive component 50 may be less than the tensile modulus of the supraspinatus tendon which is in the range of 50 MPa to 150 MPa. For example, the bioinductive component 50 may be designed to have a tensile modulus in the range of 5 MPa to 50 MPa. In some embodiments, the tensile modulus may be approximately 10 MPa.
It is desirable in some situations to generate as much tissue as possible within anatomical constraints. In some cases where a tendon is degenerated or partially torn, tendon loads are relatively low during early weeks of rehabilitation. For example, the load may be about 100 N. The strain in the tendon due to the load during rehabilitation can be about 2%. In some of these cases, the bioinductive component 50 can be designed to have an initial ultimate tensile strength of at least about 2 MPa. The tensile strength may be designed to be no more than about 50 MPa and no less than about 5 MPa with a failure load of approximately 50 N to 100 N. The compressive modulus may be designed to be at least about 0.2 MPa. Similarly, the suture pull-out strength may be relatively low. For example, the suture pull-out strength may be in the range of 5 N to 15 N.
In some embodiments, the bioinductive component 50 comprises one or more bioabsorbable materials. Examples of bioabsorbable materials that may be suitable in some applications include those in the following list, which is not exhaustive: polylactide, poly-L-lactide (PLLA), poly-D-lactide (PDLA), polyglycolide (PGA), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester; poly(amino acids), poly(alphahydroxy acid) or related copolymers materials. In some embodiments, the hydrothermal transition temperature may be selected to provide a desired absorption time. For example, a hydrothermal transition temperature of approximately 60° Celsius (° C.) may provide an absorption time in the range of 3 to 6 months.
The bioinductive component 50 may be configured to allow loading and retention of biologic growth factors. The bioinductive component 50 and/or the growth factors may be configured to controllably release the growth factors. The bioinductive component 50 may be configured to allow transmission of body fluid to remove any degradation by-products in conjunction with a potential elution profile of biologics. The bioinductive component 50 may also include platelet rich plasma at the time of implant or other biologic factor to promote healing and tissue formation.
One material and format for the sheet-like structure of the bioinductive component 50 is shown in
The second, or higher-strength, component 52 may be generally stronger than the first component 50, having both a higher initial tensile strength and a higher initial tensile modulus than the first component 50. For example, the second component 52 may have a tensile strength approximately equal to the tensile strength of the supraspinatus tendon, which may be in the range of 20 MPa to 30 MPa. The tensile strength of the second component 52 may be four to five times greater than the tensile strength of the bioinductive component. The second component 52 may have a failure load in the range of 200 N to 300 N.
To accomplish the desired degree of load sharing, the initial tensile modulus of the second component 52 should be in the same general range as the tensile modulus of the tendon. For example, the second component 52 may have a tensile modulus in the range of 50 MPa to 150 MPa. This may allow the initial load on the implant 25 to be in the range of 50% or more. It is contemplated that the implant 25 may need to carry loads in the range of 20 N to 80 N during rehabilitation.
The suture pull-out strength of the second component 52 may be higher than the suture pull-out strength of the first component 50. For example, the suture pull-out strength of all of the sutures combined needs to be sufficient to support the load of a worst case scenario (e.g. attachment of the implant to both bone and tendon). As noted above, the implant 25 may need to carry loads of up to 80 N. If four sutures are used to affix the implant 25, each suture would need a pull out strength in the range of about 20 N. It is contemplated that the suture pull-out strength may be increase by bonding or “welding” the first and second components 50, 52 together around the perimeter thereof.
The second component 52 may be designed to provide stress protection until the repaired tendon reattaches to the humeral head. This may occur over a time period of 3 to 6 months. Thus, the second component 52 may maintain its strength for at least 3 to 6 months, and in some instances, longer and then begins to biodegrade. The second component 52 may comprise one or more bioabsorbable materials. Examples of bioabsorbable materials that may be suitable in some applications include those in the following list, which is not exhaustive: polylactide, poly-L-lactide (PLLA), poly-D-lactide (PDLA), polyglycolide (PGA), polydioxanone, polycaprolactone, polygluconate, polylactic acid-polyethylene oxide copolymers, modified cellulose, collagen, poly(hydroxybutyrate), polyanhydride, polyphosphoester; poly(amino acids), poly(alphahydroxy acid) or related copolymers materials. In some embodiments, the hydrothermal transition temperature may be selected to provide a desired absorption time. It is contemplated that the second component 52 may be absorbed more slowly than the bioinductive component 50. For example, the second component 52 may be completely absorbed in about one year. This is just an example. In some instances, the second component 52 may be formed of a material that is not bioabsorbable. The material of the second component 52 selected should be highly pure and have excellent biocompatibility in order to avoid and adverse inflammatory response.
One material and format for the sheet-like structure of the second component 52 is shown in
In some embodiments, the second, high-strength, component 52 may include a decellularized dermal graft. Suitable decellularized dermal grafts may include a Conexa™ xenograft manufactured by Tornier, Inc. or Graftjacket® allograft manufactured by Wright Medical, Inc. It is contemplated that if a decelluarlized dermal graft is used as the second component 52, mechanical conditioning may be required to remove slack in the material. Due to this initial slack, current dermal grafts undergo about 20% to 30% elongation before they carry any significant load. For the purposes of the present invention, dermal grafts would need to be pre-stretched to remove the slack and delivered to the surgical site without reverting to the pre-stretched condition. Further processing may also be required in order to improve the purity of the material. The material should be highly pure and have excellent biocompatibility in order to avoid an adverse inflammatory response. The decellularized dermal graft could also be processed to incorporate fenestrations in order to create channels for tissue ingrowth.
In other embodiments, the second high-strength component 52 may include a synthetic implant. A suitable synthetic implant may include a woven mesh of poly-L-lactic acid, such as the X-Repair product manufactured by Synthasome. It is contemplated that if a synthetic implant is used as the second component 52, mechanical conditioning may be required to remove slack in the material, as described above for dermal grafts.
It is contemplated that the second component 52 may be formed of the same material as the first component 50. However, the mechanical properties of the second component 52 may be different from those of the first component 50. For example, the second component 52 may be made denser, less porous, and/or have increased cross-linking relative to the first component 50 to provide a material having increased strength, as detailed above. However, in some embodiments, the first component 50 and the second component 52 may be formed from different materials.
As discussed above, the implant 25 may be formed from a layer of a first bioinductive component 50 and a second higher strength component 52. In some instances, the higher strength component 52 may be layered on top of the bioinductive component 50. When the implant 25 is positioned within the body, the bioinductive component 50 is placed into contact with the tendon to encourage tissue in-growth. In some embodiments, the second component 52 may be a high strength modification of the first component 50. For example, the second component 52 may be formed of the same material as the first component 50, but have a higher density, lower porosity, and/or an increased degree of cross-linking relative to the first component 50. As discussed above, the implant 25 may have a thickness T in the range of 1 mm to 3 mm when dehydrated. In some embodiments, the first component 50 and the second component 52 may have the same thickness. For example, the first component 50 may have a thickness of 1 mm and the second component 52 may also have a thickness of 1 mm. In other embodiments, the second component 52 may have a greater thickness than the first component 50, or vice versa. Increasing the thickness of the second, higher strength component 52 may increase the tensile strength of the implant 25.
In some embodiment's, the implant 25 may be formed by collecting fibers, such as, but not limited to, collagen fibers, on a rotating mandrel 100, as shown in
In other embodiments, the first component 50 and the second component 52 may be formed as separate layers. The layers 50, 52 may then be stacked one on top of the other and freeze-dried or lyophilized to form a composite. The composite is then cross-linked to form a link or bond between the first component 50 and the second component 52. The link or bond between the first component 50 and the second component 52 does not need to be a high-strength interface. The bond only needs to be sufficient enough to hold the two components 50, 52 together to enable handling during surgery. As such, freeze-drying wet components 50, 52 after they have been stacked one on top of the other may sufficiently bond (at least temporarily) the two components to enable the implant 25 to be surgically implanted. Alternatively, the two components 50, 52 may be stitched together using, for example, bioabsorbable suture material. It is contemplated that stitching the components 50, 52 may be used in combination with or in place of the freeze-drying and/or cross-linking.
It is contemplated that if the high-strength component 52 is formed of the same material as the bioinductive component 50 and is made stronger by increased cross-linking, the components 50, 52 may need to be produced and cross-linked separately. The two components 50, 52 may then be laminated or bonded as described above.
According to aspects of the present detailed disclosure, methods of treating a complete or partial thickness tear in a tendon are also provided. In some methods, supraspinatus tendons having complete tears, partial thickness tears of greater than 50% and/or partial thickness tears of less than 50% are treated. The treatment site may be first arthroscopically accessed in the area of the damaged tendon. A tendon repair implant, such as previously described may be placed over a partial tear in a tendon. In some embodiments, the implant may be placed over a tendon having complete or partial tear(s), abrasions and/or inflammation. Left untreated, minor or partial tendon tears may progress into larger or full tears. According to aspects of the present disclosure, a complete or partial tear may be treated by protecting it with a tendon repair implant as described above. Such treatment can promote healing and provided immediate strength to the tendon, as well as prevent more extensive damage from occurring to the tendon, thereby averting the need for a more involved surgical procedure.
For arthroscopic delivery of the tendon repair implant, the implant may be configured to be collapsible so that it may be inserted into or mounted on a tubular member for arthroscopic insertion to the treatment site. For example, the implant and associated delivery device may be collapsed like an umbrella where the deployed delivery systems unfolds the pleats of the implant as mounted thereon to allow surface to surface engagement with the tendon without any substantial wrinkles. Once flat against the tendon, the tendon repair implant may then be affixed using sutures or other suitable means such as staples such that the tensile properties will assure that the anatomical load will be shared because the native tendon and implant experience the same strain under load.
In summary, the tendon repair implant may comprise an absorbable material. In some embodiments, the purpose of the implant is to protect an injured portion of a tendon during healing, provide an implant for new tissue growth, and/or temporarily share some of the tendon loads. The implant may induce additional tendon-like tissue formation, thereby adding strength and reducing pain, micro strains and inflammation. When implanted, the implant 25 may provide immediate strength to the tendon and transfer the load to the native tendon as the tendon heals and the implant 25 biodegrades. In some embodiments, organized collagen fibers are created that remodel to tendon-like tissue or neo-tendon with cell vitality and vascularity. Initial stiffness of the device may be less than that of the native tendon so as to not overload the fixation while tendon tissue is being generated.
Material(s) used in the implanted device should be able to withstand the compression and shear loads consistent with accepted post surgical shoulder motions. The perimeter of the device may have different mechanical properties than the interior of the device, such as for facilitating better retention of sutures, staples or other fastening mechanisms. The material(s) may be chosen to be compatible with visual, radiographic, magnetic, ultrasonic, or other common imaging techniques. The material(s) may be capable of absorbing and retaining growth factors with the possibility of hydrophilic coatings to promote retention of additives.
It is to be understood that even though numerous characteristics of various embodiments have been set forth in the foregoing description, together with details of the structure and function of various embodiments, this detailed description is illustrative only, and changes may be made in detail, especially in matters of structure and arrangements of parts illustrated by the various embodiments to the full extent indicated by the broad general meaning of the terms in which the appended claims are expressed.
This application is a continuation of U.S. application Ser. No. 17/124,961, filed Dec. 17, 2020, which is a continuation of U.S. application Ser. No. 16/156,281, filed on Oct. 10, 2018, which is a continuation of U.S. application Ser. No. 15/181,612, filed on Jun. 14, 2016, which claims the benefit of U.S. Provisional Application No. 62/175,829, filed on Jun. 15, 2015, the disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
511238 | Hieatzman et al. | Dec 1893 | A |
765793 | Ruckel | Jul 1904 | A |
1728316 | Von Wachenfeldt | Sep 1929 | A |
1855546 | File | Apr 1932 | A |
1868100 | Goodstein | Jul 1932 | A |
1910688 | Goodstein | May 1933 | A |
1940351 | Howard | Dec 1933 | A |
2034785 | Wappler | Mar 1936 | A |
2075508 | Davidson | Mar 1937 | A |
2131321 | Hart | Sep 1938 | A |
2158242 | Maynard | May 1939 | A |
2199025 | Conn | Apr 1940 | A |
2201610 | Dawson, Jr. | May 1940 | A |
2254620 | Miller | Sep 1941 | A |
2277931 | Moe | Mar 1942 | A |
2283814 | La Place | May 1942 | A |
2316297 | Southerland et al. | Apr 1943 | A |
2421193 | Gardner | May 1947 | A |
2570497 | Senderowitz | Oct 1951 | A |
2571813 | Austin | Oct 1951 | A |
2630316 | Foster | Mar 1953 | A |
2684070 | Kelsey | Jul 1954 | A |
2744251 | Vollmer | May 1956 | A |
2790341 | Keep et al. | Apr 1957 | A |
2817339 | Sullivan | Dec 1957 | A |
2825162 | Flood | Mar 1958 | A |
2881762 | Lowrie | Apr 1959 | A |
2910067 | White | Oct 1959 | A |
3068870 | Levin | Dec 1962 | A |
3077812 | Dietrich | Feb 1963 | A |
3103666 | Bone | Sep 1963 | A |
3123077 | Alcamo | Mar 1964 | A |
3209754 | Brown | Oct 1965 | A |
3221746 | Noble | Dec 1965 | A |
3470834 | Bone | Oct 1969 | A |
3527223 | Shein | Sep 1970 | A |
3570497 | Lemole | Mar 1971 | A |
3577837 | Bader, Jr. | May 1971 | A |
3579831 | Stevens et al. | May 1971 | A |
3643851 | Green et al. | Feb 1972 | A |
3687138 | Jarvik | Aug 1972 | A |
3716058 | Tanner, Jr. | Feb 1973 | A |
3717294 | Green | Feb 1973 | A |
3757629 | Schneider | Sep 1973 | A |
3777538 | Weatherly et al. | Dec 1973 | A |
3837555 | Green | Sep 1974 | A |
3845772 | Smith | Nov 1974 | A |
3875648 | Bone | Apr 1975 | A |
3960147 | Murray | Jun 1976 | A |
3976079 | Samuels et al. | Aug 1976 | A |
4014492 | Rothfuss | Mar 1977 | A |
4127227 | Green | Nov 1978 | A |
4259959 | Walker | Apr 1981 | A |
4263903 | Griggs | Apr 1981 | A |
4265226 | Cassimally | May 1981 | A |
4317451 | Cerwin et al. | Mar 1982 | A |
4400833 | Kurland | Aug 1983 | A |
4422567 | Haynes | Dec 1983 | A |
4454875 | Pratt et al. | Jun 1984 | A |
4480641 | Failla et al. | Nov 1984 | A |
4485816 | Krumme | Dec 1984 | A |
4526174 | Froehlich | Jul 1985 | A |
4549545 | Levy | Oct 1985 | A |
4570623 | Ellison et al. | Feb 1986 | A |
4595007 | Mericle | Jun 1986 | A |
4624254 | McGarry et al. | Nov 1986 | A |
4627437 | Bedi et al. | Dec 1986 | A |
4632100 | Somers et al. | Dec 1986 | A |
4635637 | Schreiber | Jan 1987 | A |
4669473 | Richards et al. | Jun 1987 | A |
4696300 | Anderson | Sep 1987 | A |
4719917 | Barrows et al. | Jan 1988 | A |
4738255 | Goble et al. | Apr 1988 | A |
4741330 | Hayhurst | May 1988 | A |
4762260 | Richards et al. | Aug 1988 | A |
4799495 | Hawkins et al. | Jan 1989 | A |
4809695 | Gwathmey et al. | Mar 1989 | A |
4851005 | Hunt et al. | Jul 1989 | A |
4858608 | McQuilkin | Aug 1989 | A |
4884572 | Bays et al. | Dec 1989 | A |
4887601 | Richards | Dec 1989 | A |
4924866 | Yoon | May 1990 | A |
4930674 | Barak | Jun 1990 | A |
4968315 | Gatturna | Nov 1990 | A |
4976715 | Bays et al. | Dec 1990 | A |
4994073 | Green | Feb 1991 | A |
4997436 | Oberlander | Mar 1991 | A |
5002563 | Pyka et al. | Mar 1991 | A |
5013316 | Goble et al. | May 1991 | A |
5015249 | Nakao et al. | May 1991 | A |
5037422 | Hayhurst et al. | Aug 1991 | A |
5041129 | Hayhurst et al. | Aug 1991 | A |
5046513 | Gatturna et al. | Sep 1991 | A |
5053047 | Yoon | Oct 1991 | A |
5059206 | Winters | Oct 1991 | A |
5062563 | Green et al. | Nov 1991 | A |
5100417 | Cerier et al. | Mar 1992 | A |
5102421 | Anspach, Jr. | Apr 1992 | A |
5116357 | Eberbach | May 1992 | A |
5122155 | Eberbach | Jun 1992 | A |
5123913 | Wilk et al. | Jun 1992 | A |
RE34021 | Mueller et al. | Aug 1992 | E |
5141515 | Eberbach | Aug 1992 | A |
5141520 | Goble et al. | Aug 1992 | A |
5156609 | Nakao et al. | Oct 1992 | A |
5156616 | Meadows et al. | Oct 1992 | A |
5167665 | McKinney | Dec 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5171273 | Silver et al. | Dec 1992 | A |
5174295 | Christian et al. | Dec 1992 | A |
5174487 | Rothfuss et al. | Dec 1992 | A |
5176682 | Chow | Jan 1993 | A |
5176692 | Wilk et al. | Jan 1993 | A |
5203787 | Noblitt et al. | Apr 1993 | A |
5217472 | Green et al. | Jun 1993 | A |
5224946 | Hayhurst et al. | Jul 1993 | A |
5242457 | Akopov et al. | Sep 1993 | A |
5246441 | Ross et al. | Sep 1993 | A |
5251642 | Handlos | Oct 1993 | A |
5261914 | Warren | Nov 1993 | A |
5269753 | Wilk | Dec 1993 | A |
5269783 | Sander | Dec 1993 | A |
5282829 | Hermes | Feb 1994 | A |
5289963 | McGarry et al. | Mar 1994 | A |
5290217 | Campos | Mar 1994 | A |
5304187 | Green et al. | Apr 1994 | A |
5333624 | Tovey | Aug 1994 | A |
5342396 | Cook | Aug 1994 | A |
5350400 | Esposito et al. | Sep 1994 | A |
5352229 | Goble et al. | Oct 1994 | A |
5354292 | Braeuer et al. | Oct 1994 | A |
5364408 | Gordon | Nov 1994 | A |
5366460 | Eberbach | Nov 1994 | A |
5370650 | Tovey et al. | Dec 1994 | A |
5372604 | Trott | Dec 1994 | A |
5380334 | Torrie et al. | Jan 1995 | A |
5383477 | DeMatteis | Jan 1995 | A |
5397332 | Kammerer et al. | Mar 1995 | A |
5403326 | Harrison et al. | Apr 1995 | A |
5405360 | Tovey | Apr 1995 | A |
5411522 | Trott | May 1995 | A |
5411523 | Goble | May 1995 | A |
5417691 | Hayhurst | May 1995 | A |
5417712 | Whittaker et al. | May 1995 | A |
5425490 | Goble et al. | Jun 1995 | A |
5441502 | Bartlett | Aug 1995 | A |
5441508 | Gazielly et al. | Aug 1995 | A |
5456720 | Schultz et al. | Oct 1995 | A |
5464403 | Kieturakis et al. | Nov 1995 | A |
5478354 | Tovey et al. | Dec 1995 | A |
5486197 | Le et al. | Jan 1996 | A |
5497933 | DeFonzo et al. | Mar 1996 | A |
5500000 | Feagin et al. | Mar 1996 | A |
5501695 | Anspach, Jr. et al. | Mar 1996 | A |
5503623 | Tilton, Jr. | Apr 1996 | A |
5505735 | Li | Apr 1996 | A |
5507754 | Green et al. | Apr 1996 | A |
5520700 | Beyar et al. | May 1996 | A |
5522817 | Sander et al. | Jun 1996 | A |
5545180 | Le et al. | Aug 1996 | A |
5560532 | DeFonzo et al. | Oct 1996 | A |
5562689 | Green et al. | Oct 1996 | A |
5569306 | Thal | Oct 1996 | A |
5582616 | Bolduc et al. | Dec 1996 | A |
5584835 | Greenfield | Dec 1996 | A |
5618314 | Harwin et al. | Apr 1997 | A |
5622257 | Deschenes et al. | Apr 1997 | A |
5628751 | Sander et al. | May 1997 | A |
5643319 | Green et al. | Jul 1997 | A |
5643321 | McDevitt | Jul 1997 | A |
5647874 | Hayhurst | Jul 1997 | A |
5649963 | McDevitt | Jul 1997 | A |
5662683 | Kay | Sep 1997 | A |
5667513 | Torrie et al. | Sep 1997 | A |
5674245 | Ilgen | Oct 1997 | A |
5681342 | Benchetrit | Oct 1997 | A |
5702215 | Li | Dec 1997 | A |
5713903 | Sander et al. | Feb 1998 | A |
5720753 | Sander et al. | Feb 1998 | A |
5725541 | Anspach, III et al. | Mar 1998 | A |
5741282 | Anspach, III et al. | Apr 1998 | A |
5766246 | Mulhauser et al. | Jun 1998 | A |
5782864 | Lizardi | Jul 1998 | A |
5797909 | Michelson | Aug 1998 | A |
5797931 | Bito et al. | Aug 1998 | A |
5797963 | McDevitt | Aug 1998 | A |
5807403 | Beyar et al. | Sep 1998 | A |
5830221 | Stein et al. | Nov 1998 | A |
5836961 | Kieturakis et al. | Nov 1998 | A |
5868762 | Cragg et al. | Feb 1999 | A |
5873891 | Sohn | Feb 1999 | A |
5885258 | Sachdeva et al. | Mar 1999 | A |
5885294 | Pedlick et al. | Mar 1999 | A |
5893856 | Jacob et al. | Apr 1999 | A |
5904696 | Rosenman | May 1999 | A |
5919184 | Tilton, Jr. | Jul 1999 | A |
5922026 | Chin | Jul 1999 | A |
5928244 | Tovey et al. | Jul 1999 | A |
5948000 | Larsen et al. | Sep 1999 | A |
5957939 | Heaven et al. | Sep 1999 | A |
5957953 | Dipoto et al. | Sep 1999 | A |
5968044 | Nicholson et al. | Oct 1999 | A |
5980557 | Iserin et al. | Nov 1999 | A |
5989265 | Bouquet De La Joliniere et al. | Nov 1999 | A |
5997552 | Person et al. | Dec 1999 | A |
6063088 | Winslow | May 2000 | A |
6156045 | Ulbrich et al. | Dec 2000 | A |
6179840 | Bowman | Jan 2001 | B1 |
6193731 | Oppelt et al. | Feb 2001 | B1 |
6193733 | Adams | Feb 2001 | B1 |
6245072 | Zdeblick et al. | Jun 2001 | B1 |
6302885 | Essiger | Oct 2001 | B1 |
6312442 | Kieturakis et al. | Nov 2001 | B1 |
6315789 | Cragg | Nov 2001 | B1 |
6318616 | Pasqualucci et al. | Nov 2001 | B1 |
6322563 | Cummings et al. | Nov 2001 | B1 |
6325805 | Ogilvie et al. | Dec 2001 | B1 |
6387113 | Hawkins et al. | May 2002 | B1 |
6391333 | Li et al. | May 2002 | B1 |
6413274 | Pedros | Jul 2002 | B1 |
6425900 | Knodel et al. | Jul 2002 | B1 |
6436110 | Bowman et al. | Aug 2002 | B2 |
6447522 | Gambale et al. | Sep 2002 | B2 |
6447524 | Knodel et al. | Sep 2002 | B1 |
6478803 | Kapec et al. | Nov 2002 | B1 |
6482178 | Andrews et al. | Nov 2002 | B1 |
6482210 | Skiba et al. | Nov 2002 | B1 |
6506190 | Walshe | Jan 2003 | B1 |
6511499 | Schmieding et al. | Jan 2003 | B2 |
6517564 | Grafton et al. | Feb 2003 | B1 |
6524316 | Nicholson et al. | Feb 2003 | B1 |
6527795 | Lizardi | Mar 2003 | B1 |
6530933 | Yeung et al. | Mar 2003 | B1 |
6540769 | Miller, III | Apr 2003 | B1 |
6551333 | Kuhns et al. | Apr 2003 | B2 |
6554852 | Oberlander | Apr 2003 | B1 |
6569186 | Winters et al. | May 2003 | B1 |
6575976 | Grafton | Jun 2003 | B2 |
6599286 | Campin et al. | Jul 2003 | B2 |
6620185 | Harvie et al. | Sep 2003 | B1 |
6629988 | Weadock | Oct 2003 | B2 |
6638297 | Huitema | Oct 2003 | B1 |
6648893 | Dudasik | Nov 2003 | B2 |
6666872 | Barreiro et al. | Dec 2003 | B2 |
6673094 | McDevitt et al. | Jan 2004 | B1 |
6685728 | Sinnott et al. | Feb 2004 | B2 |
6692506 | Ory et al. | Feb 2004 | B1 |
6702215 | Stamm et al. | Mar 2004 | B2 |
6723099 | Goshert | Apr 2004 | B1 |
6726704 | Loshakove et al. | Apr 2004 | B1 |
6726705 | Peterson et al. | Apr 2004 | B2 |
6740100 | Demopulos et al. | May 2004 | B2 |
6746472 | Frazier et al. | Jun 2004 | B2 |
6764500 | Muijs Van De Moer et al. | Jul 2004 | B1 |
6770073 | McDevitt et al. | Aug 2004 | B2 |
6779701 | Bailly et al. | Aug 2004 | B2 |
6800081 | Parodi | Oct 2004 | B2 |
6835206 | Jackson | Dec 2004 | B2 |
6849078 | Durgin et al. | Feb 2005 | B2 |
6887259 | Lizardi | May 2005 | B2 |
6926723 | Mulhauser et al. | Aug 2005 | B1 |
6932834 | Lizardi et al. | Aug 2005 | B2 |
6939365 | Fogarty et al. | Sep 2005 | B1 |
6946003 | Wolowacz et al. | Sep 2005 | B1 |
6949117 | Gambale et al. | Sep 2005 | B2 |
6964685 | Murray et al. | Nov 2005 | B2 |
6966916 | Kumar | Nov 2005 | B2 |
6972027 | Fallin et al. | Dec 2005 | B2 |
6984241 | Lubbers et al. | Jan 2006 | B2 |
6991597 | Gellman et al. | Jan 2006 | B2 |
7008435 | Cummins | Mar 2006 | B2 |
7021316 | Leiboff | Apr 2006 | B2 |
7025772 | Gellman et al. | Apr 2006 | B2 |
7033379 | Peterson | Apr 2006 | B2 |
7037324 | Martinek | May 2006 | B2 |
7048171 | Thornton et al. | May 2006 | B2 |
7063711 | Loshakove et al. | Jun 2006 | B1 |
7083638 | Foerster | Aug 2006 | B2 |
7087064 | Hyde | Aug 2006 | B1 |
7112214 | Peterson et al. | Sep 2006 | B2 |
7118581 | Fridén | Oct 2006 | B2 |
7144413 | Wilford et al. | Dec 2006 | B2 |
7144414 | Harvie et al. | Dec 2006 | B2 |
7150750 | Damarati | Dec 2006 | B2 |
7153314 | Laufer et al. | Dec 2006 | B2 |
7160314 | Sgro et al. | Jan 2007 | B2 |
7160326 | Ball | Jan 2007 | B2 |
7163551 | Anthony et al. | Jan 2007 | B2 |
7163563 | Schwartz et al. | Jan 2007 | B2 |
7169157 | Kayan | Jan 2007 | B2 |
7189251 | Kay | Mar 2007 | B2 |
7201754 | Stewart et al. | Apr 2007 | B2 |
7214232 | Bowman et al. | May 2007 | B2 |
7226469 | Benavitz et al. | Jun 2007 | B2 |
7229452 | Kayan | Jun 2007 | B2 |
7247164 | Ritchart et al. | Jul 2007 | B1 |
7303577 | Dean | Dec 2007 | B1 |
7309337 | Colleran et al. | Dec 2007 | B2 |
7320692 | Bender et al. | Jan 2008 | B1 |
7320701 | Haut et al. | Jan 2008 | B2 |
7322935 | Palmer et al. | Jan 2008 | B2 |
7326231 | Phillips et al. | Feb 2008 | B2 |
7343920 | Toby et al. | Mar 2008 | B2 |
7368124 | Chun et al. | May 2008 | B2 |
7377934 | Lin et al. | May 2008 | B2 |
7381213 | Lizardi | Jun 2008 | B2 |
7390329 | Westra et al. | Jun 2008 | B2 |
7399304 | Gambale et al. | Jul 2008 | B2 |
7404824 | Webler et al. | Jul 2008 | B1 |
7416554 | Lam et al. | Aug 2008 | B2 |
7452368 | Liberatore et al. | Nov 2008 | B2 |
7460913 | Kuzma et al. | Dec 2008 | B2 |
7463933 | Wahlstrom et al. | Dec 2008 | B2 |
7465308 | Sikora et al. | Dec 2008 | B2 |
7481832 | Meridew et al. | Jan 2009 | B1 |
7485124 | Kuhns et al. | Feb 2009 | B2 |
7497854 | Gill et al. | Mar 2009 | B2 |
7500972 | Voegele et al. | Mar 2009 | B2 |
7500980 | Gill et al. | Mar 2009 | B2 |
7500983 | Kaiser et al. | Mar 2009 | B1 |
7503474 | Hillstead et al. | Mar 2009 | B2 |
7506791 | Omaits et al. | Mar 2009 | B2 |
7559941 | Zannis et al. | Jul 2009 | B2 |
7572276 | Lim et al. | Aug 2009 | B2 |
7585311 | Green et al. | Sep 2009 | B2 |
7766208 | Epperly et al. | Aug 2010 | B2 |
7771440 | Ortiz et al. | Aug 2010 | B2 |
7776057 | Laufer et al. | Aug 2010 | B2 |
7780685 | Hunt et al. | Aug 2010 | B2 |
7785255 | Malkani | Aug 2010 | B2 |
7807192 | Li et al. | Oct 2010 | B2 |
7819880 | Zannis et al. | Oct 2010 | B2 |
7918879 | Yeung et al. | Apr 2011 | B2 |
8114101 | Criscuolo et al. | Feb 2012 | B2 |
8197837 | Jamiolkowski et al. | Jun 2012 | B2 |
8801801 | Datta et al. | Aug 2014 | B2 |
8821537 | Euteneuer et al. | Sep 2014 | B2 |
8864780 | Euteneuer et al. | Oct 2014 | B2 |
9033201 | Euteneuer | May 2015 | B2 |
9095337 | Euteneuer et al. | Aug 2015 | B2 |
9101460 | Euteneuer et al. | Aug 2015 | B2 |
9107661 | Euteneuer et al. | Aug 2015 | B2 |
9113977 | Euteneuer et al. | Aug 2015 | B2 |
9125650 | Euteneuer et al. | Sep 2015 | B2 |
9198751 | Euteneuer et al. | Dec 2015 | B2 |
9204940 | Euteneuer et al. | Dec 2015 | B2 |
9247978 | Euteneuer et al. | Feb 2016 | B2 |
9271726 | Euteneuer | Mar 2016 | B2 |
9314314 | Euteneuer et al. | Apr 2016 | B2 |
9314331 | Euteneuer et al. | Apr 2016 | B2 |
9370356 | Euteneuer et al. | Jun 2016 | B2 |
20020077687 | Ahn | Jun 2002 | A1 |
20020090725 | Simpson et al. | Jul 2002 | A1 |
20020123767 | Prestel | Sep 2002 | A1 |
20020165559 | Grant et al. | Nov 2002 | A1 |
20030073979 | Naimark et al. | Apr 2003 | A1 |
20030125748 | Li et al. | Jul 2003 | A1 |
20030212456 | Lipchitz et al. | Nov 2003 | A1 |
20040059416 | Murray et al. | Mar 2004 | A1 |
20040138705 | Heino et al. | Jul 2004 | A1 |
20040167519 | Weiner et al. | Aug 2004 | A1 |
20040267277 | Zannis et al. | Dec 2004 | A1 |
20050015021 | Shiber | Jan 2005 | A1 |
20050049618 | Masuda et al. | Mar 2005 | A1 |
20050051597 | Toledano | Mar 2005 | A1 |
20050059996 | Bauman et al. | Mar 2005 | A1 |
20050060033 | Vacanti et al. | Mar 2005 | A1 |
20050107807 | Nakao | May 2005 | A1 |
20050113736 | Orr et al. | May 2005 | A1 |
20050113938 | Jamiolkowski et al. | May 2005 | A1 |
20050171569 | Girard et al. | Aug 2005 | A1 |
20050187576 | Whitman et al. | Aug 2005 | A1 |
20050240222 | Shipp | Oct 2005 | A1 |
20050274768 | Cummins et al. | Dec 2005 | A1 |
20060074423 | Alleyne et al. | Apr 2006 | A1 |
20060178743 | Carter | Aug 2006 | A1 |
20060235442 | Huitema | Oct 2006 | A1 |
20060293760 | DeDeyne | Dec 2006 | A1 |
20070078477 | Heneveld, Sr. et al. | Apr 2007 | A1 |
20070083236 | Sikora et al. | Apr 2007 | A1 |
20070112361 | Schonholz et al. | May 2007 | A1 |
20070179531 | Thornes | Aug 2007 | A1 |
20070185506 | Jackson | Aug 2007 | A1 |
20070190108 | Datta et al. | Aug 2007 | A1 |
20070219558 | Deutsch | Sep 2007 | A1 |
20070270804 | Chudik | Nov 2007 | A1 |
20070288023 | Pellegrino et al. | Dec 2007 | A1 |
20080027470 | Hart et al. | Jan 2008 | A1 |
20080051888 | Ratcliffe et al. | Feb 2008 | A1 |
20080065153 | Allard et al. | Mar 2008 | A1 |
20080090936 | Fujimura et al. | Apr 2008 | A1 |
20080125869 | Paz et al. | May 2008 | A1 |
20080135600 | Hiranuma et al. | Jun 2008 | A1 |
20080173691 | Mas et al. | Jul 2008 | A1 |
20080188874 | Henderson | Aug 2008 | A1 |
20080188936 | Ball et al. | Aug 2008 | A1 |
20080195119 | Ferree | Aug 2008 | A1 |
20080200949 | Hiles et al. | Aug 2008 | A1 |
20080241213 | Chun et al. | Oct 2008 | A1 |
20080272173 | Coleman et al. | Nov 2008 | A1 |
20080306408 | Lo | Dec 2008 | A1 |
20090001122 | Prommersberger et al. | Jan 2009 | A1 |
20090012521 | Axelson, Jr. et al. | Jan 2009 | A1 |
20090030434 | Paz et al. | Jan 2009 | A1 |
20090069806 | De La Mora Levy et al. | Mar 2009 | A1 |
20090076541 | Chin et al. | Mar 2009 | A1 |
20090105535 | Green et al. | Apr 2009 | A1 |
20090112085 | Eby | Apr 2009 | A1 |
20090134198 | Knodel et al. | May 2009 | A1 |
20090156986 | Trenhaile | Jun 2009 | A1 |
20090156997 | Trenhaile | Jun 2009 | A1 |
20090182245 | Zambelli | Jul 2009 | A1 |
20090242609 | Kanner | Oct 2009 | A1 |
20100063599 | Brunelle et al. | Mar 2010 | A1 |
20100145367 | Ratcliffe | Jun 2010 | A1 |
20100147922 | Olson | Jun 2010 | A1 |
20100163598 | Belzer | Jul 2010 | A1 |
20100191332 | Euteneuer et al. | Jul 2010 | A1 |
20100241227 | Euteneuer et al. | Sep 2010 | A1 |
20100249801 | Sengun et al. | Sep 2010 | A1 |
20100256675 | Romans | Oct 2010 | A1 |
20100256777 | Patta et al. | Oct 2010 | A1 |
20100274278 | Fleenor et al. | Oct 2010 | A1 |
20100292715 | Nering et al. | Nov 2010 | A1 |
20100292791 | Lu et al. | Nov 2010 | A1 |
20100312250 | Euteneuer et al. | Dec 2010 | A1 |
20100312275 | Euteneuer et al. | Dec 2010 | A1 |
20100327042 | Amid et al. | Dec 2010 | A1 |
20110000950 | Euteneuer et al. | Jan 2011 | A1 |
20110004221 | Euteneuer et al. | Jan 2011 | A1 |
20110011917 | Loulmet | Jan 2011 | A1 |
20110034942 | Levin et al. | Feb 2011 | A1 |
20110040310 | Levin et al. | Feb 2011 | A1 |
20110040311 | Levin et al. | Feb 2011 | A1 |
20110066166 | Levin et al. | Mar 2011 | A1 |
20110106154 | DiMatteo et al. | May 2011 | A1 |
20110114700 | Baxter, III et al. | May 2011 | A1 |
20110184530 | Datta et al. | Jul 2011 | A1 |
20110224702 | Van Kampen et al. | Sep 2011 | A1 |
20110264149 | Pappalardo et al. | Oct 2011 | A1 |
20120029537 | Mortarino | Feb 2012 | A1 |
20120100200 | Belcheva et al. | Apr 2012 | A1 |
20120160893 | Harris et al. | Jun 2012 | A1 |
20120193391 | Michler et al. | Aug 2012 | A1 |
20120209401 | Euteneuer et al. | Aug 2012 | A1 |
20120211543 | Euteneuer | Aug 2012 | A1 |
20120248171 | Bailly et al. | Oct 2012 | A1 |
20120316608 | Foley | Dec 2012 | A1 |
20130153627 | Euteneuer et al. | Jun 2013 | A1 |
20130153628 | Euteneuer | Jun 2013 | A1 |
20130158554 | Euteneuer et al. | Jun 2013 | A1 |
20130158587 | Euteneuer et al. | Jun 2013 | A1 |
20130158661 | Euteneuer et al. | Jun 2013 | A1 |
20130172920 | Euteneuer et al. | Jul 2013 | A1 |
20130172997 | Euteneuer et al. | Jul 2013 | A1 |
20130184716 | Euteneuer et al. | Jul 2013 | A1 |
20130240598 | Euteneuer et al. | Sep 2013 | A1 |
20130245627 | Euteneuer et al. | Sep 2013 | A1 |
20130245682 | Euteneuer et al. | Sep 2013 | A1 |
20130245683 | Euteneuer et al. | Sep 2013 | A1 |
20130245706 | Euteneuer et al. | Sep 2013 | A1 |
20130245707 | Euteneuer et al. | Sep 2013 | A1 |
20130245762 | Van Kampen et al. | Sep 2013 | A1 |
20130245774 | Euteneuer et al. | Sep 2013 | A1 |
20140371853 | Kampen et al. | Dec 2014 | A1 |
20150313705 | Euteneuer et al. | Nov 2015 | A1 |
20160228608 | Hakimi et al. | Aug 2016 | A1 |
Number | Date | Country |
---|---|---|
2390508 | May 2001 | CA |
0142225 | May 1985 | EP |
0298400 | Jan 1989 | EP |
0390613 | Oct 1990 | EP |
0543499 | May 1993 | EP |
0548998 | Jun 1993 | EP |
0557963 | Sep 1993 | EP |
0589306 | Mar 1994 | EP |
0908152 | Apr 1999 | EP |
1491157 | Dec 2004 | EP |
1559379 | Aug 2005 | EP |
2030576 | Mar 2009 | EP |
2154688 | Sep 1985 | GB |
2397240 | Jul 2004 | GB |
58188442 | Nov 1983 | JP |
2005586122 | Mar 2005 | JP |
2006515774 | Jun 2006 | JP |
8505025 | Nov 1985 | WO |
0176456 | Oct 2001 | WO |
0234140 | May 2002 | WO |
2003105670 | Dec 2003 | WO |
2004000138 | Dec 2003 | WO |
2004093690 | Nov 2004 | WO |
2005016389 | Feb 2005 | WO |
2006086679 | Aug 2006 | WO |
2007014910 | Feb 2007 | WO |
2007030676 | Mar 2007 | WO |
2007078978 | Jul 2007 | WO |
2007082088 | Jul 2007 | WO |
2008111073 | Sep 2008 | WO |
2008111078 | Sep 2008 | WO |
2008139473 | Nov 2008 | WO |
2009079211 | Jun 2009 | WO |
2009143331 | Nov 2009 | WO |
2010081029 | Jul 2010 | WO |
2011095890 | Aug 2011 | WO |
2011128903 | Oct 2011 | WO |
Entry |
---|
“Rotator Cuff Tear,” Wikipedia, the free encyclopedia, 14 pages, Downloaded on Dec. 6, 2012. |
Alexander et al., “Ligament and tendon repair with an absorbable polymer-coated carbon fiber stent,” Bulletin of the Hospital for Joint Diseases Orthopaedic Institute, 46(2):155-173, 1986. |
Bahler et al., “Trabecular bypass stents decrease intraocular pressure in cultured himan anterior segments,” Am. J. Opthamology, 138(6):988-994, Dec. 2004. |
Chamay et al., “Digital contracture deformity after implantation of a silicone prosthesis: Light and electron microscopic study,” The Journal of Hand Surgery, 3(3):266-270, May 1978. |
D'Ermo et al., “Our results of the operation of ab externo,” Opthalmologica, 168: 347-355, 1971. |
Finnan et al., “Partial-thickness rotator cuff tears,” J. Shoulder Elbow Surg. vol. 19: 609-616, 2010. |
France et al., “Biomechanical evaluation of rotator cuff fixation methods,” The American Journal of Sports Medicine, 17(2), 1989. |
Goodship et al., “An assessment of filamentous carbon fibre for the treatment of tendon injury in the horse,” Veterinary Record, 106: 217-221, Mar. 8, 1980. |
Junter et al., “Flexor-tendon reconstruction in severely damaged hands,” The Journal of Bone and Joint Surgery (American Volume), 53-A(5): 329-358, Jul. 1971. |
Johnstone et al., “Microsurgery of Schlemm's canal and the human aqueous outflow system,” Am. J. Opthamology, 76(6): 906-917, Dec. 1973. |
Kowalsky et al., “Evaluation of suture abrasion against rotator cuff tendon and proximal humerus bone,” Arthroscopy: The Journal of Arthroscopic and Related Surgery, 24(3):329-334, Mar. 2008. |
Lee et al., “Aqueous-venous and intraocular pressure. Preliminary report of animal studies,” Investigative Opthalmology, 5(1): 59-64, Feb. 1966. |
Maepea et al., “The pressures in the episcleral veins, Schlemm's canal and the trabecular meshwork in monkeys: Effects of changes in intraocular pressure,” Exp. Eye Res., 49:645-663, 1989. |
Nicolle et al., “A silastic tendon prosthesis as an adjunct to flexor tendon grafting: An experimental and clinical evaluation,” British Journal of Plastic Surgery, 22(3-4):224-236, 1969. |
Rubin et al., “The use of acellular biologic tissue patches in foot and ankle surgery,” Clinics in Podiatric Medicine and Surgery, 22:533-552, 2005. |
Schultz, “Canaloplasty procedure shows promise for open-angle glaucoma in European study,” Ocular Surgery News, 34-35, Mar. 1, 2007. |
Spiegel et al., “Schlemm's canal implant: a new method to lower intraocular pressure in patients with POAG,” Opthalmic Surgery and Lasers, 30(6):492-494, Jun. 1999. |
Stenson et al., “Arthroscopic treatment of partial rotator cuff tears,” Operative Techniques in Sports Medicine, 12(2):135-148, Apr. 2004. |
Valdez et al., “Repair of digital flexor tendon lacerations in the horse, using carbon fiber implants,” JAYMA, 177(5):427-435, Sep. 1, 1980. |
Zobitz et al., “Determination of the compressive materials properties of the supraspinatus tendon,” J. Biomech. Eng., vol. 123(1): Feb. 2001. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for Application No. PCT/US2016/037354, 2016. 11 pages, dated Aug. 25, 2016. |
Number | Date | Country | |
---|---|---|---|
20230190446 A1 | Jun 2023 | US |
Number | Date | Country | |
---|---|---|---|
62175829 | Jun 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17124961 | Dec 2020 | US |
Child | 18112802 | US | |
Parent | 16156281 | Oct 2018 | US |
Child | 17124961 | US | |
Parent | 15181612 | Jun 2016 | US |
Child | 16156281 | US |